SCHEMBL7066382

SCHEMBL7066382

CC(C)CC(NS(=O)(=O)c1ccc(CNC(=O)c2ccccc2)s1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 7/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CCKBR P32239 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP2C19 P33261 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
ADAMTS4 O75173 1/20 0.43
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.41
CTSL P07711 2/20 0.41
CA2 P00918 2/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14519924 0.79 MEN1 (0.52) MEN1KMT2ACCKBRKDM4EALDH1A1
SCHEMBL7451657 0.78 MEN1 (0.51) MEN1KMT2ACCKBRKDM4EALDH1A1
SCHEMBL13881587 0.77 MEN1 (0.54) MEN1KMT2ACCKBRKDM4EALDH1A1
SCHEMBL7061397 0.77 MMP2 (0.51) MEN1KMT2AKDM4EALDH1A1CYP2C19
SCHEMBL7460244 0.77 CCKBR (0.50) MEN1KMT2ACCKBRKDM4EHPGD
SCHEMBL8033818 0.76 HPGD (0.54) MEN1KMT2ACCKBRKDM4EALDH1A1
SCHEMBL7062243 0.75 KDM4E (0.54) MEN1KMT2AKDM4EALDH1A1CYP2C19
SCHEMBL1742958 0.75 HPGD (0.52) MEN1KMT2ACCKBRHPGDCA2
Hydrochloric Acid SCHEMBL28187724 0.75 HPGD (0.52) MEN1KMT2ACCKBRKDM4EALDH1A1
SCHEMBL1742818 0.75 HPGD (0.52) MEN1KMT2ACCKBRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 ITGAV 4527/4885MEN1 1180/4885KMT2A 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.